University of Texas MD Anderson Cancer Center

OpenWorks @ MD Anderson
OncoLog MD Anderson's Report to Physicians

Research Medical Library

1-1983

Oncolog, Volume 28, Number 01, January-March 1983
The University of Texas MD Anderson Cancer Center
James M. Bowen
The University of Texas MD Anderson Cancer Center

Follow this and additional works at: https://openworks.mdanderson.org/oncolog
Part of the History of Science, Technology, and Medicine Commons, and the Oncology Commons

Recommended Citation
The University of Texas MD Anderson Cancer Center and Bowen, James M., "Oncolog, Volume 28,
Number 01, January-March 1983" (1983). OncoLog MD Anderson's Report to Physicians. 1.
https://openworks.mdanderson.org/oncolog/1

This Newsletter is brought to you for free and open access by the Research Medical Library at OpenWorks @ MD
Anderson. It has been accepted for inclusion in OncoLog MD Anderson's Report to Physicians by an authorized
administrator of OpenWorks @ MD Anderson. For more information, please contact rml-help@mdanderson.org.

A REPORT TO PHYSICIANS-------....

□ nc □ Log
January-March 1983

THE UNIVERSITY OF TEXAS SYSTEM CANCER CENTER
M. D. ANDERSON HOSPITAL AND TUMOR INSTITUTE

Volume 28, Number 1

Newsletter Becomes OncoLog
by James M. Bowen, PhD, Vice
President for Academic Affairs
This is the first issue of Oncolog, a
report to all physicians regarding the
status of cancer research and treatment at The University of Texas System Cancer Center M. D. Anderson
Hospital and Tumor Institute. Formerly called the Newsletter and distributed bimonthly, Oncolog becomes, with this issue, a quarterly
publication.
As a publication of the UT Cancer
Center, Oncolog has been redesigned to meet the needs of our
readers more effectively. The educational value of the contents
wi ll be emphasized to keep you informed of advances. in
diagnosis and treatment methods at UT MDAH. Its mission will be
to present the most recent developments in patient care, significant diagnostic progress, and current clinical and basic science
research activities. It will also serve to keep you informed about
continuing cancer education conferences being held at UT

rl°e·wsletter

MDAH that may be of interest and
value to you.

The UT Cancer Center was originally established to serve as a major
referral hospital as well as a clinical
and basic science research facility,
with the fourfold mission of patient
care, education, research, and prevention. The Office of Academic Affairs is responsible for the dissemination of current and relevant information that will aid the physician in
the early detection of cancer and the
follow-up treatment of cancer patients. Oncolog will continually strive to serve as a significant resource for the physician
in maintaining current oncologic knowledge in professional practice.
We encourage your active participation in Oncolog and invite
you to suggest topics to be included in future issues. With your
cooperation and assistance, Oncolog will achieve its goal of
serving as an educational aid to you, the physician.

Prolactinoma, a Prevalent Gonadoinhibitory
Tumor, Responds Well to Treatment
Prolactinoma, a benign, prolactin-producing pituitary tumor, is
the most common tumor in the human body and occurs in 30% of
the population. Since 1969, when human prolactin was first
isolated~·· physicians at UT MDAH have successfully treated
approximately 350 patients with prolactinoma, which can be a
cause of sterility in both men and women .
Prolactinoma produces excess prolactin in the body and has
both an indirect and direct effect on the gonads, according to
Naguib A. Samaan, MD, PhD, chief of the Section of Endocrinology in the Department of Internal Medicine. The increased
prolactin level indirectly affects the gonads by acting on the
hypothalamus to prevent the pulsatile production of the luteinizing hormone releasing factor, while it directly inhibits formation of
sperm and ova at the gonadal level and suppresses gonadal
steroidogenesis.
In women, the combination of these effects may cause
infertility, menstrual irregularity, galactorrhea, reduction of vaginal
secretions, or painful intercourse. Men may suffer infertility,
impotency, or, in rare instances, galactorrhea or gynecomastia. In
children, prolactinoma may inhibit normal growth and sexual
development. In addition, individuals with large, invasive prolac-

tinomas, which destroy the pituitary tissue and bulge outside the
pituitary fossa, may develop impaired lateral vision, brain compression, headaches, rupture in the sphenoid sinus causing
rhinorrhea, or other endocrine-related disorders. If a patient
exhibits any of these symptoms or has a family history of pituitary
tumors, hypercalcemia, and pancreatic tumors, the attending
physician should suspect the presence of prolactinoma and refer
the patient to an appropriate treatment center for diagnostic
testing, particularly since some cases of prolactinoma may be
familial or may be a component of Type 1 multiple endocrine
neoplasia, according to Dr Samaan.
A primary diagnostic tool to detect prolactinoma, used at UT
MDAH and at other hospitals treating patients with the disease, is
a radioimmunoassay that measures the level of serum prolactin,
a test that Dr Samaan established soon after prolactin was
isolated in humans. To obtain an accurate measurement of a
patient's serum prolactin level, physicians at UT MDAH perform
the test at least three times while the patient's serum prolactin is
at basal level and then four additional times after injecting the
patient with thyrotropic releasing hormone (TRH). Patients with
Continued on page 2

Prolactinoma.
Continued from page 1

prolactinoma have basal serum prolactin levels that are higher
than normal and blunted serum prolactin responses after TRH
stimulation. Because high prolactin levels may also be caused by
oral contraceptives, analgesics, hypotensive agents, or hypothyroidism, standard procedure requires analysis of serum prolactin
levels two months after patients cease taking d,rugs that may
affect the level. Plasma estradiol in the women and testosterone
in men are also measured, since they are usually suppressed in
patients with prolactinoma. If the disease is suspected, sophisticated x-ray methods are used to confirm the diagnosis.
The two most common radiographic methods employed at UT
MDAH to diagnose prolactinoma are computed axial tomography
(CAT) and polytomography. These methods clearly delineate the
pituitary gland and can reveal a tumor as well as suprasellar
extension. The results of these procedures determine the appropriate treatment-either drug therapy or surgery-for each patient.
If the prolactinoma is not visible on the polytomogram or CAT
scan but the patient exhibits many of the symptoms of the
disease, he or she may have hyperplasia of the prolactinproducing cells or a prolactin-producing microadenoma, a small
pituitary tumor 1 cm or less in diameter. Under these circumstances, the patient receives bromocriptine, a drug that inhibits
prolactin secretion from the pituitary gland. Physicians at UT
MDAH do not perform exploratory surgery to confirm the existence of a microadenoma; the risk of damaging the pituitary gland,
though slight, is not worth the· potential benefits, according to Dr
Samaan.
Bromocriptine relieves the symptoms in 90% of the patients
who receive it-those with hyperplasia or microadenomas not
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demonstrable by x-ray, those not wishing to undergo surgery, and
those not responding to surgery. Menstruation begins or returns
in women, and fertility is restored in both men and women.
Evidence indicates that bromocriptine may even shrink a pituitary
tumor, although it is not a cure for prolactinoma; if the patient
stops taking the drug, the prolactin level rises again . Although the
drug does not cause any severe reactions in patients or
congenital defects in children of women who take the drug, it may
cause nausea, vomiting, diarrhea, or syncope, especially when
first taken. Therefore, bromocriptine is administered in small,
gradually increasing doses so that the patient may build up a
tolerance to it.
If the tumor is visible on the polytomogram or CAT scan and the
patient is willing to undergo surgery, transphenoidal microdissection is performed, using the microscopic undervision dissection
technique. This method enables the .surgeon , to . reach Ahe
pituitary gland through an incision under the lip, into the gums,
between the septum and the surrounding mucous membrane,
through the sphenoid sinus, and into the floor of the pituitary
fossa. Ordinarily, the tumor grows superficially from the anteroinferior aspect of the pituitary gland and when removed leaves the
normal pituitary tissue intact.
After surgery, the patient usually recovers quickly and returns
home on the fourth day. Four to 12 weeks later, most symptoms
disappear and prolactin levels return to normal in 85% of the
cases. Of the responding patients who desire to have children,
85% to 90% do so without complication. In adolescent female
patients whose sexual development was inhibited, menarche
begins soon after surgery, and in both male and female adolescents, secondary sexual characteristics appear. Those patients
who do not respond to surgery, usually those with large invasive
tumors, receive bromocriptine to inhibit high prolactin levels. Men
and women beyond the reproductive age may receive adjuvant
radiotherapy.
Although physicians have been very successful in treating
patients with prolactinoma, its cause remains a mystery, according to Dr Samaan. Studies at UT MDAH have shown that
symptoms often appear in women who have high estrogen levels,
naturally occurring during pregnancy or produced exogenously
byJ;,ir:tt:u :ont~oLi:1Ws~ 1.11 addlti.Qn, .tl;le.incisiAAge. .oJ ,t/:1.i .i:.Ji~e~e.j§
four times greater in women than in men. Although Dr Samaan
does not directly implicate excess estrogen as a cause of
prolactinoma, animal experiments have shown that estrogen can
produce hyperplasia or a microadenoma from prolactin-producing cells. In women, estrogen may unmask a preexisting
asymptomatic prolactinoma or may stimulate development of
potential tumor cells.
While studies at UT MDAH may eventually lead to an understanding of the cause and prevention of the disease, Dr Samaan
now focuses on treating individuals with prolactinoma. Based on
postmortem studies, 25% of the population suffers from prolactinoma without ever knowing they have the disease, he explained, adding that many of these individuals marry and ·
needlessly remain childless.
(Physicians desiring additional information should write or call
Naguib A. Samaan, MD, PhD, Department of Internal Medicine,
MDAH Box 65, The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030, (713) 792-2840.-ED)
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Laboratory Research Continues to Advance
Methods of Cancer Diagnosis and Therapy
by James M. Bowen, PhD, Vice President for Academic Affairs
In a recent presentation, Dr Bowen responded to questions
about the future of cancer research. His examination of recent
technology developed through basic science and its successful
application to cancer diagnosis and treatment confirmed his
optimism about that future . Here he summarizes the presentation.
A friend who is a medical reporter recently asked me, "Don't
you think it's true that cancer research has topped out? We've
admittedly made a number of important accomplishments over
the past 20 or 30 years, and now we're trying to apply those
accomplishments as best we can, but we really don't have much
to look forward to over the next 10 or 20 years."
My competitive spirit was aroused, and I made a fairly detailed
analysis of new technologies based on basic cancer research. I
hope to convince you that cancer research is in a time of
explosive advancement, producing new understandings and new
technologic capabilities that will change the field forever. I could
use many examples for this, but the ones I have chosen
represent: (1) major advances in our understanding of biologic
systems, (2) major advances in our ability to exploit these
understandings with new or recently evolving technology, and (3)
particular applications of basic research and their rapid translation into the patient care area.
I want to begin with a brief description of the basis for a cancer
cell's behavior. A fact that we take for granted, but which has
particular significance in the context of understanding cancer, is
that all the complex tissues and functioning systems that comprise the living body originate from a single cell. A sperm cell and
an egg unite to produce an embryonic cell, and that original cell
begins to divide, entering a period of tremendous proliferation. A
series of highly ordered, highly regulated changes then begins to
oc·cur in subsets of the cell population so that highly differentiated
tissues arise.
The important common denominator of differentiation is that all
of the information needed to become any specialized cell in the
body resides in every cell of the body. For that reason, an
extremely complex and highly inclusive regulatory system must
exist so that a kidney cell remains a kidney cell and so that if that
kidney cell dies, it is replaced with a kidney cell and not a brain
cell or a muscle cell. For every tissue there must be at least one
gene for a substance that instructs those cells of that specific
tissue to remain in place, to produce their products or carry out
their specified function. When those cells divide to replace cells
lost to aging or damage, the regulatory gene must control
replacement with the appropriate kind of cell. An aberration in
that regulatory activity can produce aberration in differentiation.
One of the characteristics of the evolving differentiation sequence is that cells become less and less prone to grow and
proliferate, less and less competitive with other cells in their
environment, and more and more focused on their functional
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activity. Kidney cells grow only to keep up with the body's growth
or to replace lost kidney cells. Loss of either the functional aspect
of the product of that regulatory gene or of the ability of that cell to
respond to the signals from that regulatory gene tends to reverse
the cell's progress on the path of differentiation, changing it to a
more proliferative, more competitive, less functionally focused
cell. When that functional backtracking reaches a certain level,
the cell is no longer normal but rather possesses the behavioral
characteristics we associate with disease, particularly with cancer.
Now let me briefly review the background of cancer therapy.
The original modality of cancer therapy was surgery. When it was
discovered that tissues were susceptible to destruction by x-rays,
gamma rays, and other sources of radiation and that rapidly
proliferating tissues were more sensitive to radiation than normal
tissues, radiotherapy became an important second modality. It
extended the ability to kill tumor cells, allowed therapeutic
measures to be taken in areas inaccessible to the surgeon, and
helped us to control distant spread and metastasis.
In the late 1940s and early 1950s, chemotherapy was added to
the treatment choices. The basis for chemotherapy, like that of
radiotherapy, is that the most rapidly proliferating cells are the
most sensitive to cytotoxic substances, while normal, more
differentiated, nonproliferative cells are more likely to survive.
Also much like radiotherapy, chemotherapy extended the physician's ability to treat cancer that had spread or was too small or
inaccessible for surgery. Many new drugs have proved effective,
and many treatment advances have come from careful studies of
the optimal combination of chemotherapy with surgery and radiotherapy.
Within the past 20 years, attention has also turned to manipulation of the body's immunologic defenses against tumor cells.
These early studies have suggested a fourth therapeutic modality, immunotherapy, which encompasses our attempts to understand, exploit, and augment the body's own defenses. From
there, we have enlarged our conceptual views to include a broad
area that we term biologic response modification, defined as any
therapeutic approach that augments any of the body's defenses
against external encroachment or internal aberration.
Let me emphasize that biologic response modification is
complementary to surgery, radiotherapy, and chemotherapy. The
initial tumor burden must be reduced by surgery, by radiotherapy,
or by chemotherapy before biologic response modifiers can be
used to control those last few tumor cells and to prevent
recurrence of either that same tumor or another tumor.
Interferons are the most remarkable biologic response modifiers we have studied. They represent the cell's own system for
defending itself against the encroachment of a virus or other
substance or agent that mimics foreign genetic material. Interferon does not act on the cell in which it is made: Interferon is in fact
a "messenger molecule" that leaves the cell in which it is induced
and is taken up by a recipient cell. The recipient cell responds to
Continued on page 6
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Radiotherapy Plays Vital Role in Treatment
Adjunctive radiotherapy for patients with malignant epithelial
tumors of the parotid gland greatly reduces the risk of tumor
recurrence after surgery, according to a recent retrospective
study conducted at UT MDAH . The study also verified that the
facial nerve, when not grossly involved, can be safely preserved
with irradiation, even when its proximity to such a tumor might
indicate otherwise. The study was conducted by Oscar M.
Guillamondegui, MD, Department of Head and Neck Surgery,
and Gilbert H. Fletcher, MD, Mary Jane Oswald, BS, David
McNaney, MD, and Marsha D. McNeese, MD, all of the Department of Radiotherapy.
Adjunctive radiotherapy has been used systematically ·at UT
MDAH since the middle 1960s for selected patients with malignant parotid tumors. Until recently, however, adequate evaluation
of its controlling effect has been difficult, according to Dr
Guillamondegui, because parotid tumors sometimes recur many
years after initial treatment. Consequently, the precise role of
irradiation for these patients has remained unclear, and no
recommended treatment program has been widely accepted .
Therefore, this study was undertaken to determine the overall
benefit of adjunctive radiotherapy for patients with malignant
epithelial tumors of the parotid gland and to clarify the clinical
situations in which its use is effective.
Records of 77 patients (35 males and 42 females between 10
and 80 years of age) admitted to UT MDAH between 1954 and
1977 with malignant epithelial parotid tumors were reviewed. All
patients had been treated with surgery and adjunctive irradiation
at the site of the parotid gland (5000-6000 rad, usually using the
electron beam in combination with 60Co or 18-25 MeV photons) .
Fifty-six patients had received additional irradiation (5000-6000

rad) to the cervical lymph nodes. The total number of local and
regional recurrences were calculated; tumor recurrences were
then related to histologic type and grade of disease, extent of
residual disease, and extent of facial nerve resection.
The results of the study indicated that adjunctive radiotherapy
greatly reduces the recurrence rate of malignant parotid tumors:
The overall control rate was 87%. Of the 77 patients, only six had
recurrences in the primary site and four had recurrences in the
cervical lymph nodes, yielding a local recurrence rate of 7.8%
and a regional recurrence rate of 5.2%. (One patient had both
local and regional recurrence and was included in both groups.)
This local recurrence 'rate is at least four ' tirries less than •·Iocal ' '
recurrence rates reported for patients treated with surgery alone.
No definite correlation between histologic type of tumor and
tumor recurrence was found , although slightly more recurrences
appeared in patients with adenocarcinomas. The different cell
types and the number of local and regional recurrences of each
were as follows : malignant mixed tumors, 1 local recurrence in 13
patients; adenocarcinomas, 3 local and 2 regional recurrences in
17 patients; low-grade mucoepidermoid carcinomas, O recurrences in 9 patients; high-grade mucoepidermoid carcinomas, 1
local and 2 regional recurrences in 15 patients ; acinic cell
carcinomas, O recurrences in 5 patients; adenocystic carcinomas, 1 local recurrence in 15 patients; unclassified tumors, O
recurrences in 1 patient; and other types, 0 recurrences in 2
patients. These findings indicate that the various histologic types
of malignant epithelial parotid tumors are radiosensitive.
A correlation between tumor radiosensitivity and histologic
grade of tumor (high grade, low grade, or unknown) was
determined based on the number of mitoses per high power field .
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of Patients with Malignant Parotid Tumors
Of the 77 patients included in the study, 63 had tumors of a
histologically high grade, and all 10 local and regional recurrences developed in patients from this group. The low-grade
mucoepidermoid and acinic cell carcinomas, which are noninvasive and slow-growing, did not recur.
Adjunctive radiotherapy was also found to be effective in
controlling limited residual disease, often present in or near the
surgical margin or in nerve sheaths after excision of the parotid
tumor mass. As support for this finding, the study showed no
correlation between extent of residual disease and tumor recurrence, as follows: gross residual disease, 1 local and 1 regional
recurrence in 14 patients; microscopic residual disease, 2 local
and 1 reg ional recurrence in 26 patients; no residual disease, 3
local and 2 regional recurrences in 33 patients; and unknown
amount of residual disease, 0 recurrences in 4 patients.
A most important finding, which again illustrates irradiation's
control of residual disease, should settle the controversy surrounding facial nerve preservation in these patients, a practice
that often precludes total ablation of parotid tumor cells: Patients
whose facial nerves had been preserved had no higher incidence
of tumor recurrence. Thus, in most patients, possible or known
residual disease on or near the nerve sheath had been controlled
by irradiation.
Preservation of this vital nerve, which runs through the parotid
gland, has been a primary concern of physicians who treat
patients with malignant parotid tumors, according to Dr Guillamondegui. With complete resection of the facial nerve, which
supplies motor fibers to all facial muscles, the patient suffers
facial paralysis. Therefore, in many instances, the preferred
treatment has been to preserve this nerve, if not grossly involved,
and to control potential residual disease in the nerve area with
irradiation.
Confirming the benefit of this approach, the study related the
extent of facial nerve resection to the number of local and
regional recurrences, as follows : total facial nerve resection, 3
local and 2 regional recurrences in 21 patients; partial facial
nerve resection, 1 local and 1 regional recurrence in 21 patients;
no facial nerve resection, 2 local and 1 regional recurrence in 35
patients.
Also of concern was whether the complications of adjunctive
radiotherapy were too severe to warrant its application . Of the
total patient population, only five, all of whom received adjunctive
radiotherapy for extensive disease, suffered some long-term
complications: osteonecrosis (two patients), soft-tissue necrosis
(one patient), necrosis of the brain and temporomandibular joint
(one patient), and myelitis (one patient). Three patients have
been successfully treated for these complications; the patient
with necrosis of the brain and the temporomandibular joint
continues to suffer severe side effects; myelitis in another caused
his death. These complications might have been minimized had
the more advanced radiotherapy techniques used today been
available.

part of the treatment plan for selected patients with malignant
parotid tumors: those with histologically high-grade tumors,
locally invasive or metastatic disease, or gross or microscopic
residual disease. The study has also established that, in selected
patients, adjunctive radiotherapy allows the surgeon to preserve
the facial nerve without increasing the risk of recurrence.
(Physicians desiring additional information should write or call
Oscar M. Guillamondegui, MD, Department of Head and Neck
Surgery, MDAH Box 69, The University of Texas M. D. Anderson
Hospital and Tumor Institute at Houston, 6723 Bertner Avenue,
Houston, Texas 77030, (713) 792-6920.-ED)

The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
DEPARTMENT OF PEDIATRICS

8th Mental Health Conference

Life, Faith,
Hope, and Magic
The Chaplaincy in a Children's
Cancer Center
April 21-22, 1983
Shamrock Hilton Hotel
Houston, Texas
Cochairpersons: Jan van Eys, MD, PhD, Department of
Pediatrics, and Edward J. Mahnke, DD, Department of
Chaplaincy and Pastoral Education
Interviews with parents and children during and after the
experience with cancer indicate that religion is a primary
source of support. Therefore, this conference will focus on
the role of clergy members as an integral part of the health
care team.
For registration information, write or call the Office of
Conference Services, HMB Box 131 , The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.

The study has confirmed that adjunctive radiotherapy is a vital
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Research.
Continued from page 3
the message by synthesizing a secondary protein that confers
resistance.
We have identified two key areas of antiviral interferon activity.
The so-called antiviral proteins, or inhibitory proteins, are produced against early stages of virus replication . These stages are
so early that they are common to most viruses, which allows for a
broad spectrum of interferon-induced resistance. For example, if
interferon production is induced in the cell by influenza virus, that
cell is not only resistant to influenza virus but to virtually every
other virus.
Perhaps more important from the standpoint of cancer therapy
is the fact that interferons not only recognize foreign genes and
induce resistance in recipient cells, they also recognize aberrant
genetic behavior patterns in uninfected cells. Thus, they act
against the proliferative uncontrolled growth phases in cells such
as some cancer cells.
Interferons inhibit the growth of cells in tissue culture. They
inhibit the same tumor cells in a susceptible animal that they
inhibit in culture. They may also inhibit normal cells that are in
highly proliferative states, such as cells of the blood-forming
tissues, cells of the gastric and colonic mucosa, hair-producing
cells, and so on. But interferons are more effective inhibitors of
tumor cells than of normal cells because the proliferation rates of
tumor cells are often much higher than those of even the most
rapidly proliferating normal cells in the body.
Interferons are also immunomodulators. They inhibit both the
proliferation and function of some kinds of immune cells and
enhance the proliferation and function of others. (Figure 1
summarizes these activities of interferon.) The immunomodula-

Figure 1

BIOLOGIC ACTIONS OF
INTERFERON
ANTIVIRAL
• Trinucleotide synthetase
• Protein kinases

ANTI PROLIFERATIVE
• In vitrer-inhibits cells in monolayer suspension
•In viver-inhibits tumor cells and normal cells
IMMUNOMODULATION
• Inhibition
(primary and secondary antibody responses)
(lymphocyte blastogenesis)
• Enhancement
(macrophage function)
(sensitized cyotoxic lymphocytes)
(natural killer cells)
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tory property is a two-edged sword , however, since large
quantities of interferons may produce immune compromise.
Nevertheless, the interferons are extremely important biologic
response modifiers, which have already shown therapeutic
benefits for breast cancer, melanoma, multiple myeloma, and a
variety of other tumors.
One problem exists with interferon, however-it is species
specific. In the early 1960s, drug companies committed millions
of dollars to the production of kilogram quantities of chick
interferon. It turned out, however, that a kilogram of chick
interferon is a useful therapeutic agent only if you happen to be
treating a sick chicken.
If we are to treat human disease with interferon we must have
human interferon. The first clinical trial of interferon exemplifies
this problem's significance: In Scandinavia about 16 years ago,
18 young patients with osteosarcoma were treated with interferon. To treat those 18 patients, all the interferon made from every
blood donation in the entire country of Finland for one full year
was needed.
It is thus very clear that if interferon is ever to be fully exploited
as a chemotherapeutic agent and for its other potentials, we must
have a larger source. How are we going to get human interferon if
we don't have human cells? Basic science has placed the answer
to that question in our hands through recombinant DNA technology. This technology is a beautiful example of the impact of basic
research on therapy for cancer and other diseases because it
was first developed as a solution to simple academic laboratory
problems with no visible relevance to the treatment of cancer or
any other disease.
In the course of their research, two scientists at Stanford
University discovered that restriction endonucleases were able to
break DNA molecules from any organism at specific points.
These pieces could then be recombined with DNA pieces from
any other organism, in any order. Since that discovery in 1973,
many more restriction endonucleases have been discovered,
each cutting DNA molecules at specific sites. Those pieces, too,
could be recombined in any order from any organism . By
inserting the resulting manufactured genes into an appropriate
organism, the products of any added foreign genes can be
expressed. (Figure 2 summarizes some of the biologic products
available through recombinant DNA technology.)
Escherichia coli is the organism most often used as the
recipient of foreign genes. It is a simple microorganism that is
easy and inexpensive to culture, and it has genes that are always
read in the same sequence-these genes are expressed absolutely predictably. When they mutate, the genes can be identified .
More important, the microorganism will express any gene, no
matter what its source, if it is inserted into its genome.
Thus, once the first human interferon gene was identified, it
became a simple matter to apply recombinant DNA technology to
splice that human gene onto the end of the bacterial chromosome. That bacterium then synthesized large quantities of human
interferon. The first clinical trial of human interferon produced by
recombinant DNA technology is under way right now. In most
respects this interferon appears to be as good as human
interferon produced by human cells.
Another area that has revolutionized an entire field of endeavor
is hybridoma technology. A quick tour of immunology will make its
significance clear: Although there are many different functional
January-March 1983
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Figure 2
RECOMBINANT DNA TECHNOLOGY
IN CANCER RESEARCH
SYNTHESIS OF BIOLOGICALLY ACTIVE AGENTS
• Interferons
• Hormones
• "Tailored" antibiotics and other drugs
SYNTHESIS AND STUDY OF GENE PRODUCTS
ASSOCIATED WITH THE MALIGNANT PROCESS
• Differentiation factors
• Phosphokinases
• Tumor cell growth factors

populations of immune cells in our bodies and in the bodies of all
complex living things, they fall into two basic populations-those
that produce antibodies (8 cells) and those that directly interact
with the target substance or target cell (T cells).
B cells have a remarkable set of properties. They contain within
thei r own genetic makeup a programmability that puts to shame
the finest computer ever devised by man. They are able to
recognize an antigen, and realizing their own interactive capability, they produce antibodies absolutely specific for the antigen.
The B cell is thus programmed, as are all generations of its
daughter cells, to produce that antibody and that antibody only. A
subpopulation of those programmed cells does stop making the
antibody, but it retains the ability to produce that antibody
whenever the body is exposed to the same antigen again.
These B cells, which reside in the spleen of highly evolved
organisms, die very rapidly, usually within a few hours, if they are
removed from the spleen. Thus, they have extremely limited
growth potential. Like other cells of the body, B cells can undergo
malignant change. The most important B cell cancer is multiple
myeloma, which is sometimes known as cancer of the bone
mauow because the malignant change occurs when the B cells
are undergoing initial development in the bone marrow.
Myeloma cells have an interesting set of properties that
contrast with those of their normal counterparts. If myeloma cells
are removed from the body, and if they are given the appropriate
nutrients, they can grow indefinitely, having lost the senescence
mechanism of the normal B cell. In addition, their growth is
unrestrained. They produce antibody protein , but in an unprogrammed form, and they produce it in quantities a hundred times
greater than does the normal spleen cell. They are also able to
grow in an appropriate animal. For example, mouse myeloma
cells can be transplanted to a mouse of the same genetic
configuration, and a new myeloma tumor will form and will keep
on growing, ultimately killing the mouse. In addition, the cells lose
the programmability of the normal cell, one of the characteristics
of cancer cells in general. While the normally differentiated cell is
focused on function, not growth, the cancer cell is focused on
unrestrained growth.
Dr Cesar Milstein, a scientist in Great Britain, asked himself a
very academic question: "What would happen if I fused a normal
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spleen cell with a multiple myeloma cell ?" What happened when
he did turned the field of immunology upside down . From his
fusing of a normal antibody-producing spleen cell and a multiple
myeloma cell, a hybridoma resulted (Figure 3). From the myeloma cell, the hybridoma obtained an indefinite life span, the
ability to grow unrestrained both in tissue culture and in a suitable
animal, and continuous immunoglobulin production capability.
From the normal spleen cell, it obtained specific programmability.
What resulted was a cellular factory that could forever produce a
specific antibody in large quantities. If a clone is produced from a
single hybrid cell, the programmability of a single B cell is
available in large quantities. The resulting monoclonal antibody
has absolute specificity.
All of the uses of this hybridoma technology for cancer therapy
depend on one of the manifestations of the difference between
cancer cells and normal cells-the expression of new chemical
signals on the surface, recognizable by the immune system. It is
possible to make monoclonal antibodies against a variety of
these signal substances-say, a marker specific for ovarian
cancer. The monoclonal antibody will not react with anything in
the body except an ovarian cancer cell. It becomes an absolutely
specific reagent for the diagnosis of ovarian cancer cells.
Monoclonal antibodies complexed to plastic spheres can be
used to select a specific antigen from a mixture of a thousand
different antigens. We can complex antibodies to a variety of
substances, dyes, radioactive atoms, and even large complex
substances such as drugs, and they do not lose their specificity.
For example, suppose a patient has an ovarian tumor. If a drug
that is potent against ovarian cancer is complexed to a monoclonal antibody specific for ovarian cancer, the drug can be
delivered through the blood stream to the ovarian tumor and
Continued on page 8

Figure 3
HYBRIDOMA CHARACTERISTICS
MYELOMA CELLS
• Indefinite life span

NORMAL SPLEEN CELLS
• Short extracorporeal life
span

• Unrestrained growth
• Continuous immunoglobulin production
• Growth in vitro and in vivo
• "Unprogrammed" immunoglobulin

• Limited growth
• Programmable for monospecific antibody
• Specificity retention for life

CLONAL
HYBRIDOMA
• Indefinite life span
• Growth in vitro and in vivo
• Continuous immunoglobulin production
• Specific, monoclonal antibody
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Research.
Continued from page 7
nowhere else. Suppose the tumor has already metastasized to
the liver, but the few hundred cells are undetectable. The
monoclonal antibody doesn't care. It will deliver the cytotoxic drug
to those few hundred cells hidden In the liver.
Another use for monoclonal antibodies Is In the programming
of killer T cells. Although there are a variety of ways these
lymphocytes are directed, the most significant Is by adsorption
to antibodies produced against a given substance; the unpro•
grammed killer cells then become specific killer cells for whatever
cell Is carrying the specific antigen. tf a few hundred molecules of
a specific antlovarlan tumor antibody produced by monoclonal
techniques are attached to a patient's lymphocytes and those
lymphocytes are returned to the patient, the killer T cells are no
longer unprogrammed. They are T cells programmed to attack
and destroy the ovarian tumor.
In certain kinds of systemic cancers, particularly those of the
blood system, fairly large amounts of monoclonal anl.ibody alone
may destroy the tumor. Or Evan Hersh and his colleagues In our
Department of Cllnlcal Immunology have Just completed a small,
limited protocol us ng monoclonal antibodies produced galnst a
marker spec! te for a partk:\Jlar k nd ol human I u em a. In some
patients, the skin reactivity ol th s leukem a completely disappeared after two or three courses ol therapy.
I witl now bring th s discussion full circle and ask you the
question that I was asked. With these advances n mind, has
cancer research realty topped out? Is there nothing to look
forward to In cancer research over the neX1 few years? The news
of cancer research's death Is greatly exaggerated, seriously
mistaken, and shortsighted. Not only does it live, but new
technology to exploit new knowledge has never been as promising. I believe new technologies will continue to change our entire
view of the management of cancer and diseases like cancer
within this century. The three kinds of cancer that produce 50% of
all cancer deaths have been most resistant to all therapies that
are now available-cancers of the lung, breast, and colon.
However, new technologies are now being applied to these
areas, particularly colon and lung cancers. We will begin to see
our first truly sucoessful inroads into the management of even
these most refractory cancers in the neX1 five to ten years.
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